FOLD
Price
$6.08
Change
-$0.01 (-0.16%)
Updated
May 8 closing price
Capitalization
1.87B
83 days until earnings call
RGNX
Price
$7.15
Change
-$0.09 (-1.24%)
Updated
May 8 closing price
Capitalization
362.85M
3 days until earnings call
Ad is loading...

FOLD vs RGNX

Header iconFOLD vs RGNX Comparison
Open Charts FOLD vs RGNXBanner chart's image
Amicus Therapeutics
Price$6.08
Change-$0.01 (-0.16%)
Volume$9.23M
Capitalization1.87B
REGENXBIO
Price$7.15
Change-$0.09 (-1.24%)
Volume$2.32M
Capitalization362.85M
FOLD vs RGNX Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. RGNX commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Buy and RGNX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (FOLD: $6.08 vs. RGNX: $7.15)
Brand notoriety: FOLD and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 239% vs. RGNX: 211%
Market capitalization -- FOLD: $1.87B vs. RGNX: $362.85M
FOLD [@Biotechnology] is valued at $1.87B. RGNX’s [@Biotechnology] market capitalization is $362.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than RGNX.

Price Growth

FOLD (@Biotechnology) experienced а -8.98% price change this week, while RGNX (@Biotechnology) price change was -27.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

FOLD is expected to report earnings on Jul 31, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($1.87B) has a higher market cap than RGNX($363M). RGNX YTD gains are higher at: -7.503 vs. FOLD (-35.456). FOLD has higher annual earnings (EBITDA): 29.4M vs. RGNX (-198.23M). FOLD has more cash in the bank: 250M vs. RGNX (235M). RGNX has less debt than FOLD: RGNX (82M) vs FOLD (444M). FOLD has higher revenues than RGNX: FOLD (528M) vs RGNX (83.3M).
FOLDRGNXFOLD / RGNX
Capitalization1.87B363M516%
EBITDA29.4M-198.23M-15%
Gain YTD-35.456-7.503473%
P/E RatioN/AN/A-
Revenue528M83.3M634%
Total Cash250M235M106%
Total Debt444M82M541%
FUNDAMENTALS RATINGS
FOLD vs RGNX: Fundamental Ratings
FOLD
RGNX
OUTLOOK RATING
1..100
710
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9394
PRICE GROWTH RATING
1..100
9160
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
34n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (68) in the Biotechnology industry is in the same range as RGNX (75). This means that FOLD’s stock grew similarly to RGNX’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that FOLD’s stock grew similarly to RGNX’s over the last 12 months.

FOLD's SMR Rating (93) in the Biotechnology industry is in the same range as RGNX (94). This means that FOLD’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's Price Growth Rating (60) in the Biotechnology industry is in the same range as FOLD (91). This means that RGNX’s stock grew similarly to FOLD’s over the last 12 months.

RGNX's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for FOLD (100). This means that RGNX’s stock grew significantly faster than FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDRGNX
RSI
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 10 days ago
70%
Bullish Trend 8 days ago
75%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIGFX21.35N/A
N/A
Fidelity International Growth
AWTCX18.65N/A
N/A
Virtus Duff & Phelps Water C
GLBLX9.14N/A
N/A
Leuthold Global Retail
NWGSX27.15N/A
N/A
Nationwide WCM Focused Sm Cp Instl Svc
TEMHX8.16N/A
N/A
Nuveen Emerging Markets Eq I

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-0.16%
VCYT - FOLD
43%
Loosely correlated
+1.20%
ROIV - FOLD
40%
Loosely correlated
-1.25%
AXON - FOLD
39%
Loosely correlated
+14.13%
ATXS - FOLD
38%
Loosely correlated
-0.45%
KRYS - FOLD
38%
Loosely correlated
+0.27%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with RCKT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-1.24%
RCKT - RGNX
62%
Loosely correlated
+11.57%
DNLI - RGNX
56%
Loosely correlated
+0.77%
ARWR - RGNX
55%
Loosely correlated
+1.45%
BEAM - RGNX
55%
Loosely correlated
+6.32%
NTLA - RGNX
53%
Loosely correlated
+13.58%
More